SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharma gets shareholders' nod to raise up to $200 million

30 Sep 2019 Evaluate

Glenmark Pharmaceuticals has received shareholders' approval to raise up to $200 million (about Rs 1,413 crore) through issuance of debt securities. The proposal was approved at the company's annual general meeting held on September 27, 2019.

According to the proposal, the company planning to raise up to $200 million in Indian and/or international market through bonds, debentures or other debt securities in one or more tranches.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2241.30 -6.60 (-0.29%)
20-Apr-2026 12:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.80
Dr. Reddys Lab 1238.75
Cipla 1238.25
Zydus Lifesciences 942.95
Lupin 2331.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×